ReNeuron Group (RENE) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Feb 2006 07:00 AM
RNS
Re: Manufacturing Contract
06 Feb 2006 07:01 AM
RNS
Research Update
24 Jan 2006 07:00 AM
RNS
Re US Patent Office
06 Dec 2005 10:03 AM
RNS
Re Conference
02 Dec 2005 11:19 AM
RNS
Re: Government Support
30 Nov 2005 07:00 AM
RNS
Interim Results
23 Nov 2005 04:57 PM
RNS
Notice of Results
18 Nov 2005 07:00 AM
RNS
Research Update
25 Oct 2005 07:00 AM
RNS
Research Update
05 Oct 2005 09:59 AM
RNS
Holding(s) in Company
22 Sep 2005 10:31 AM
RNS
Research Update
20 Sep 2005 09:13 AM
RNS
Director/PDMR Shareholding
16 Sep 2005 01:08 PM
RNS
Director/PDMR Shareholding
16 Sep 2005 01:06 PM
RNS
Director/PDMR Shareholding
16 Sep 2005 01:05 PM
RNS
Director/PDMR Shareholding
16 Sep 2005 01:03 PM
RNS
Director/PDMR Shareholding
16 Sep 2005 01:01 PM
RNS
Director/PDMR Shareholding
12 Aug 2005 07:00 AM
RNS
Admission to Trading on AIM

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

It listed on AIM in 2006 under the ticker RENE.

UK 100

Latest directors dealings